Working Together to Reduce Prescription Drug Abuse and Overdose Deaths
Leads: Brian Hurley, MD & Gary Tsai, MD
The use of psychosocial interventions in conjunction with medications approved by the Food and Drug Administration (FDA) for the treatment of addictions is an evidence-based intervention in cases of prescription drug abuse. However, the availability of these Medications for Addiction Treatment (MAT) has been limited by several factors, some of which include a shortage of qualified prescribers, a lack of knowledge about these options by patients and treatment programs, cultural resistance to the use of MAT, as well as financial and regulatory challenges.
The Medications for Addiction Treatment Action Team will:
- Increase number of buprenorphine waivered prescribers in LAC by 40 by April 2017, and 160 by 2020.
- Increase number of buprenorphine claims in the Medi-Cal system to 10,000 in LAC by April 2017, and 50,000 by 2020.